Skip to content
2000
Volume 22, Issue 2
  • ISSN: 1567-2026
  • E-ISSN: 1875-5739

Abstract

Background

With 301 million cases worldwide, anxiety disorders represent a serious public health concern. Many people endure ongoing distress while receiving several treatments because of the drawbacks of traditional therapy, such as adverse effects, dependence, and inconsistent efficacy. This emphasizes the absolute need for novel treatment approaches.

Objective

This review examines emerging pharmacological and non-pharmacological strategies for anxiety disorders, assessing existing and developing therapeutic options while examining the drawbacks of conventional therapies.

Methods

A comprehensive literature review was carried out using the NIH, PubMed, and Google Scholar databases. Studies from 2020-2025 were given priority in the inclusion criteria, with a few supporting references from earlier years. Personalized medicine, combination therapy, non-pharmacological interventions, and novel anxiolytic targets, ., were among the keywords used.

Results

Conventional therapies, including benzodiazepines, SSRIs, and SNRIs, are still the major choices, but they have significant disadvantages. The protein kinase pathway, endocannabinoid and orexin systems, NK1R antagonists, and microbiome modulation are examples of emerging targets. Emerging strategies that show preliminary promise include digital therapeutics, gene therapy, optogenetics, personalized medicine, combination therapy, herbal therapy, and peptide-based medicines (., NPY, NPS, oxytocin analogs, CRF, vasopressin, and melanocortin receptor antagonist). Several of these approaches modulate key neural circuits, such as the involvement of the amygdala–prefrontal cortex axis, the HPA axis, and biomarker-informed personalization, among others; yet many remain in early-phase or preclinical investigation. However, limited comparative data exist between these novel strategies and standard therapies, underlining the need for rigorous head-to-head evaluations.

Conclusion

Advances in molecular neuroscience and precision medicine offer potential alternatives to conventional treatments. However, most emerging therapies require further clinical validation, large-scale trials, and translational refinement before they can be integrated into real-world decision-making for anxiety disorders.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnr/10.2174/0115672026394052250808075022
2025-08-18
2026-03-09

  • From This Site

    /content/journals/cnr/10.2174/0115672026394052250808075022
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AskarizadehM.M. GholamhosseiniL. KhajoueiR. HomayeeS. AskarizadehF. AhmadianL. Determining the impact of mobile-based self-care applications on reducing anxiety in healthcare providers: A systematic review.BMC Med. Inform. Decis. Mak.20252513710.1186/s12911‑024‑02817‑4 39849432
     [Google Scholar]
  2. RazackS. KandikattuH.K. AmrutaN. KhanumF. Neuroprotective effects of Nardostachys jatamansi against BSO induced anxiety via its antioxidant machinery and by elevating catecholamines and GABA levels in mice.Curr. Tradit. Med.20217222224510.2174/2215083806999201202153612
     [Google Scholar]
  3. MuffordM.S. van der MeerD. AndreassenO.A. RamesarR. SteinD.J. DalvieS. A review of systems biology research of anxiety disorders.Br. J. Psychiatry202143441442310.1590/1516‑4446‑2020‑1090 33053074
     [Google Scholar]
  4. PetersonP.R. HoR. Nervous and scared: Understanding anxiety and trauma/stressor-related disorders and obsessive-compulsive disorders.Physician Assist. Clin.20216347949310.1016/j.cpha.2021.03.002
     [Google Scholar]
  5. AkikiT.J. JubeirJ. BertrandC. TozziL. WilliamsL.M. Neural circuit basis of pathological anxiety.Nat. Rev. Neurosci.202526152210.1038/s41583‑024‑00880‑4 39604513
     [Google Scholar]
  6. GuY. GuS. LeiY. LiH. From uncertainty to anxiety: How uncertainty fuels anxiety in a process mediated by intolerance of uncertainty.Neural Plast.2020202011810.1155/2020/8866386 33299402
     [Google Scholar]
  7. BhattS. DevadossT. ManjulaS.N. RajangamJ. 5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders.Curr. Neuropharmacol.20211991545155910.2174/1570159X18666201015155816 33059577
     [Google Scholar]
  8. MendezE.M. MillsJ.A. SureshV. StimpflJ.N. StrawnJ.R. Trajectory and magnitude of response in adults with anxiety disorders: A Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines.CNS Spectr.202429318719610.1017/S1092852924000142 38523533
     [Google Scholar]
  9. GuptaA. BhattacharyaG. FarheenS.A. Systematic review of benzodiazepines for anxiety disorders in late life.Ann. Clin. Psychiatry2020322114127 32343283
     [Google Scholar]
  10. ChakrabortyD. DasR. Drugs Acting on Central Nervous System.In: Essentials of Pharmacodynamics and Drug Action.SingaporeSpringer20248912110.1007/978‑981‑97‑2776‑6_5
     [Google Scholar]
  11. HeesbeenE.J. van KampenT. VerdouwP.M. van LissaC. BijlsmaE.Y. GroeninkL. The effect of SSRIs on unconditioned anxiety: A systematic review and meta-analysis of animal studies.Psychopharmacology202424191731175510.1007/s00213‑024‑06645‑2 38980348
     [Google Scholar]
  12. EnglerJ. FilliterC. MontastrucF. AbenhaimH. RejS. RenouxC. Risk of abnormal uterine bleeding associated with high-affinity compared with low-affinity serotonin and norepinephrine reuptake inhibitors.J. Affect. Disord.202435081382110.1016/j.jad.2024.01.163 38246277
     [Google Scholar]
  13. Also FontanetA. KostovB. Benavent ÀreuJ. Pilot psychotherapy program for the deprescription of benzodiazepines for anxiety disorders.Ansiedad Estres2021281717710.5093/anyes2022a8
     [Google Scholar]
  14. GarakaniA. MurroughJ.W. FreireR.C. Pharmacotherapy of anxiety disorders: Current and emerging treatment options.Front. Psychiatry20201159558410.3389/fpsyt.2020.595584 33424664
     [Google Scholar]
  15. NasirM. TrujilloD. LevineJ. DwyerJ.B. RuppZ.W. BlochM.H. Glutamate systems in DSM-5 anxiety disorders: Their role and a review of glutamate and GABA psychopharmacology.Front. Psychiatry20201154850510.3389/fpsyt.2020.548505 33329087
     [Google Scholar]
  16. KenwoodM.M. KalinN.H. BarbasH. The prefrontal cortex, pathological anxiety, and anxiety disorders.Neuropsychopharmacology202247126027510.1038/s41386‑021‑01109‑z 34400783
     [Google Scholar]
  17. TafetG.E. NemeroffC.B. Pharmacological treatment of anxiety disorders: The role of the HPA axis.Front. Psychiatry20201144310.3389/fpsyt.2020.00443 32499732
     [Google Scholar]
  18. KhalifehS. PourM.S. GhermezianA. Introduction to neurocircuitry and neurobiology of anxiety.Arch Adv Biosci2021121455110.22037/aab.v12i1.25279
     [Google Scholar]
  19. Georg JensenM. GoodeM. HeinrichM. Herbal medicines and botanicals for managing insomnia, stress, anxiety, and depression: A critical review of the emerging evidence focusing on the Middle East and Africa.PharmaNutrition20242910039910.1016/j.phanu.2024.100399
     [Google Scholar]
  20. ZhouY. WangG. LiangX. XuZ. Hindbrain networks: Exploring the hidden anxiety circuits in rodents.Behav. Brain Res.202411528110.1016/j.bbr.2024.115281 39374875
     [Google Scholar]
  21. AzargoonjahromiA. The role of epigenetics in anxiety disorders.Mol. Biol. Rep.202350119625963610.1007/s11033‑023‑08787‑6 37804465
     [Google Scholar]
  22. NobisA. ZalewskiD. WaszkiewiczN. Peripheral markers of depression.J. Clin. Med.2020912379310.3390/jcm9123793 33255237
     [Google Scholar]
  23. OmopoO.E. Exploring post-traumatic stress disorder: Causes, diagnostic criteria, and treatment options.Int J Acad Inf Syst Res2024873544
     [Google Scholar]
  24. ZhaoD. WangD. WangW. The altered sensitivity of acute stress induced anxiety-related behaviors by modulating insular cortex-paraventricular thalamus-bed nucleus of the stria terminalis neural circuit.Neurobiol. Dis.202217410589010.1016/j.nbd.2022.105890 36220611
     [Google Scholar]
  25. RobayoA.M. Hypotalamus-pituitary-adrenal (HPA) axes and their relationship with stress, mood, personality, and neurocognitive functioning.The Theory of Mind Under ScrutinyChamSpringer20243434136510.1007/978‑3‑031‑46742‑4_11
     [Google Scholar]
  26. SinghH. ChopraC. SinghH. Gut-brain axis and Alzheimer’s disease: Therapeutic interventions and strategies.J. Funct. Foods202411210591510.1016/j.jff.2023.105915
     [Google Scholar]
  27. ClarkT.D. ReicheltA.C. Ghosh-SwabyO. SimpsonS.J. CreanA.J. Nutrition, anxiety and hormones. Why sex differences matter in the link between obesity and behavior.Physiol. Behav.202224711371310.1016/j.physbeh.2022.113713 35066061
     [Google Scholar]
  28. ParkH.R. CaiM. YangE.J. Neurogenic interventions for fear memory via modulation of the hippocampal function and neural circuits.Int. J. Mol. Sci.2022237358210.3390/ijms23073582 35408943
     [Google Scholar]
  29. ŁośK. WaszkiewiczN. Biological markers in anxiety disorders.J. Clin. Med.2021108174410.3390/jcm10081744 33920547
     [Google Scholar]
  30. SongJ. Amygdala activity and amygdala-hippocampus connectivity: Metabolic diseases, dementia, and neuropsychiatric issues.Biomed. Pharmacother.202316211464710.1016/j.biopha.2023.114647 37011482
     [Google Scholar]
  31. AroraI. MalP. AroraP. PaulA. KumarM. GABAergic implications in anxiety and related disorders.Biochem. Biophys. Res. Commun.202472415021810.1016/j.bbrc.2024.150218 38865810
     [Google Scholar]
  32. SchieleM.A. DomschkeK. Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders.Genes Brain Behav.20181731242310.1111/gbb.12423 28873274
     [Google Scholar]
  33. SharmaR. KumarasamyM. PariharV.K. RavichandiranV. KumarN. Monoamine oxidase: A potential link in papez circuit to generalized anxiety disorders.CNS Neurol. Disord. Drug Targets202423563865510.2174/1871527322666230412105711 37055898
     [Google Scholar]
  34. KoskinenM.K. HovattaI. Genetic insights into the neurobiology of anxiety.Trends Neurosci.202346431833110.1016/j.tins.2023.01.007 36828693
     [Google Scholar]
  35. KhanM.M.A. KhanM.N. Effects of psychosocial and socio‐environmental factors on anxiety disorder among adolescents in Bangladesh.Brain Behav.202010120189910.1002/brb3.1899 33085214
     [Google Scholar]
  36. ShiH.J. WangS. WangX.P. ZhangR.X. ZhuL.J. Hippocampus: Molecular, cellular, and circuit features in anxiety.Neurosci. Bull.20233961009102610.1007/s12264‑023‑01020‑1 36680709
     [Google Scholar]
  37. SchankJ.R. Neurokinin receptors in drug and alcohol addiction.Brain Res.2020173414672910.1016/j.brainres.2020.146729 32067964
     [Google Scholar]
  38. SolomonM.G. NennigS.E. CottonM.R. WhitingK.E. FulenwiderH.D. SchankJ.R. Neurokinin-1 receptors in the nucleus accumbens shell influence sensitivity to social defeat stress and stress-induced alcohol consumption in male mice.Addict. Neurosci.20241310017410.1016/j.addicn.2024.100174 39801674
     [Google Scholar]
  39. EstebanF. Ramos-GarcíaP. MuñozM. González-MolesM.Á. Substance P and neurokinin 1 receptor in chronic inflammation and cancer of the head and neck: A review of the literature.Int. J. Environ. Res. Public Health202119137510.3390/ijerph19010375 35010633
     [Google Scholar]
  40. FaganH.A. BaldwinD.S. Pharmacological treatment of generalised anxiety disorder: Current practice and future directions.Expert Rev. Neurother.202323653554810.1080/14737175.2023.2211767 37183813
     [Google Scholar]
  41. HasbiA. MadrasB.K. GeorgeS.R. Endocannabinoid system and exogenous cannabinoids in depression and anxiety: A review.Brain Sci.202313232510.3390/brainsci13020325 36831868
     [Google Scholar]
  42. ChenC. Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.Pharmacol. Ther.202324410839410.1016/j.pharmthera.2023.108394 36966972
     [Google Scholar]
  43. DasramM.H. WalkerR.B. KhamangaS.M. Recent advances in endocannabinoid system targeting for improved specificity: Strategic approaches to targeted drug delivery.Int. J. Mol. Sci.202223211322310.3390/ijms232113223 36362014
     [Google Scholar]
  44. BasavarajappaB.S. SubbannaS. Molecular insights into epigenetics and cannabinoid receptors.Biomolecules20221211156010.3390/biom12111560 36358910
     [Google Scholar]
  45. BietarB. TannerS. LehmannC. Neuroprotection and beyond: The central role of CB1 and CB2 receptors in stroke recovery.Int. J. Mol. Sci.202324231672810.3390/ijms242316728 38069049
     [Google Scholar]
  46. BhullerR. SchlageW.K. HoengJ. Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol.J. Cannabis Res.2024614010.1186/s42238‑024‑00250‑y 39394179
     [Google Scholar]
  47. JászberényiM. ThurzóB. BagosiZ. VécseiL. TanakaM. The orexin/hypocretin system, the peptidergic regulator of vigilance, orchestrates adaptation to stress.Biomedicines202412244810.3390/biomedicines12020448 38398050
     [Google Scholar]
  48. MaruyamaT. UetaY. Internal and external modulation factors of the orexin system (REVIEW).Peptides202316517100910.1016/j.peptides.2023.171009 37054895
     [Google Scholar]
  49. AbounooriM. MaddahM.M. ArdeshiriM.R. Orexin neuropeptides modulate the hippocampal-dependent memory through basolateral amygdala interconnections.Cereb. Circ. Cogn. Behav.2022310003510.1016/j.cccb.2021.100035 36324409
     [Google Scholar]
  50. GuptaP.R. PrabhavalkarK. Combination therapy with neuropeptides for the treatment of anxiety disorder.Neuropeptides20218610212710.1016/j.npep.2021.102127 33607407
     [Google Scholar]
  51. GorkaS.M. KhorramiK.J. ManzlerC.A. PhanK.L. Acute orexin antagonism selectively modulates anticipatory anxiety in humans: Implications for addiction and anxiety.Transl. Psychiatry202212130810.1038/s41398‑022‑02090‑x 35918313
     [Google Scholar]
  52. Ten-BlancoM. FloresÁ. Pereda-PérezI. Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1.Biomed. Pharmacother.202214911292510.1016/j.biopha.2022.112925 35477218
     [Google Scholar]
  53. IssingerO.G. GuerraB. Phytochemicals in cancer and their effect on the PI3K/AKT-mediated cellular signalling.Biomed. Pharmacother.202113911165010.1016/j.biopha.2021.111650 33945911
     [Google Scholar]
  54. Martínez-AlcantarL. Hernández-PadillaL. Díaz-PérezA.L. Cyclic peptides as protein kinase modulators and their involvement in the treatment of diverse human diseases.Kinases and Phosphatases20242434637810.3390/kinasesphosphatases2040023
     [Google Scholar]
  55. RoskoskiR. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.Pharmacol. Res.202319410684710.1016/j.phrs.2023.106847 37454916
     [Google Scholar]
  56. ChenD. WangJ. CaoJ. ZhuG. cAMP-PKA signaling pathway and anxiety: Where do we go next?Cell. Signal.202412211131110.1016/j.cellsig.2024.111311 39059755
     [Google Scholar]
  57. GaoF. WangJ. YangS. JiM. ZhuG. Fear extinction induced by activation of PKA ameliorates anxiety-like behavior in PTSD mice.Neuropharmacology202322210930610.1016/j.neuropharm.2022.109306 36341808
     [Google Scholar]
  58. ZlobinA. BloodworthJ.C. OsipoC. Mitogen-Activated Protein Kinase (MAPK) Signaling.In: Predictive Biomarkers in Oncology.ChamSpringer201921322110.1007/978‑3‑319‑95228‑4_16
     [Google Scholar]
  59. IslamF. RoyS. ZehraviM. Polyphenols targeting MAP kinase signaling pathway in neurological diseases: Understanding molecular mechanisms and therapeutic targets.Mol. Neurobiol.20246152686270610.1007/s12035‑023‑03706‑z 37922063
     [Google Scholar]
  60. AminiJ. BeyerC. ZendedelA. SanadgolN. MAPK is a mutual pathway targeted by anxiety-related miRNAs, and E2F5 is a putative target for anxiolytic miRNAs.Biomolecules202313354410.3390/biom13030544 36979479
     [Google Scholar]
  61. BommarajuS. DhokneM.D. ArunE.V. SrinivasanK. SharmaS.S. DatusaliaA.K. An insight into crosstalk among multiple signalling pathways contributing to the pathophysiology of PTSD and depressive disorders.Prog. Neuropsychopharmacol. Biol. Psychiatry202413111094310.1016/j.pnpbp.2024.110943 38228244
     [Google Scholar]
  62. DashS. SyedY.A. KhanM.R. Understanding the role of the gut microbiome in brain development and its association with neurodevelopmental psychiatric disorders.Front. Cell Dev. Biol.20221088054410.3389/fcell.2022.880544 35493075
     [Google Scholar]
  63. KumarA. PramanikJ. GoyalN. Gut microbiota in anxiety and depression: Unveiling the relationships and management options.Pharmaceuticals202316456510.3390/ph16040565 37111321
     [Google Scholar]
  64. SocałaK. DoboszewskaU. SzopaA. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders.Pharmacol. Res.202117210584010.1016/j.phrs.2021.105840 34450312
     [Google Scholar]
  65. SimpsonC.A. Diaz-ArtecheC. ElibyD. SchwartzO.S. SimmonsJ.G. CowanC.S.M. The gut microbiota in anxiety and depression – A systematic review.Clin. Psychol. Rev.20218310194310.1016/j.cpr.2020.101943 33271426
     [Google Scholar]
  66. MoriP. ChauhanM. ModasiyaI. KumarV. Dietary modulation of the nervous and immune system: Role of probiotics/prebiotics/] synbiotics/postbiotics.In: Probiotics, Prebiotics, Synbiotics, and Postbiotics.SingaporeSpringer202330732810.1007/978‑981‑99‑1463‑0_16
     [Google Scholar]
  67. SharmaR. GuptaD. MehrotraR. MagoP. Psychobiotics: The next-generation probiotics for the brain.Curr. Microbiol.202178244946310.1007/s00284‑020‑02289‑5 33394083
     [Google Scholar]
  68. CoceanA-M. VodnarD.C. Exploring the gut-brain Axis: Potential therapeutic impact of Psychobiotics on mental health.Prog. Neuropsychopharmacol. Biol. Psychiatry202413411107310.1016/j.pnpbp.2024.111073
     [Google Scholar]
  69. Isaac-BamgboyeF.J. MgbechidinmaC.L. OnyeakaH. Isaac-BamgboyeI.T. ChukwugozieD.C. Exploring the potential of postbiotics for food safety and human health improvement.J. Nutr. Metab.202420241186816110.1155/2024/1868161 39139215
     [Google Scholar]
  70. Porras-GarcíaE. Fernández-Espada CalderónI. Gavala-GonzálezJ. Fernández-GarcíaJ.C. Potential neuroprotective effects of fermented foods and beverages in old age: A systematic review.Front. Nutr.202310117084110.3389/fnut.2023.1170841 37396132
     [Google Scholar]
  71. MerkourisE. MavroudiT. MiliotasD. Probiotics’ effects in the treatment of anxiety and depression: A comprehensive review of 2014–2023 clinical trials.Microorganisms202412241110.3390/microorganisms12020411 38399815
     [Google Scholar]
  72. HuangF. WuX. Brain neurotransmitter modulation by gut microbiota in anxiety and depression.Front. Cell Dev. Biol.2021964910310.3389/fcell.2021.649103 33777957
     [Google Scholar]
  73. PinhoL.G. LopesM.J. CorreiaT. Patient-centered care for patients with depression or anxiety disorder: An integrative review.J. Pers. Med.202111877610.3390/jpm11080776 34442420
     [Google Scholar]
  74. RadosavljevicM. Svob StracD. JancicJ. SamardzicJ. The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy.Genes2023145109510.3390/genes14051095 37239455
     [Google Scholar]
  75. SugandhF.N.U. ChandioM. RaveenaF.N.U. Advances in the management of diabetes mellitus: A focus on personalized medicine.Cureus20231584369710.7759/cureus.43697 37724233
     [Google Scholar]
  76. Scherf-ClavelM. WeberH. DeckertJ. Erhardt-LehmannA. The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics.Expert Opin. Drug Metab. Toxicol.202117111249126010.1080/17425255.2021.1991912 34643143
     [Google Scholar]
  77. TomasiJ. LisowayA.J. ZaiC.C. Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics.J. Psychiatr. Res.2019119334710.1016/j.jpsychires.2019.09.002 31563039
     [Google Scholar]
  78. KalungiA. WomersleyJ.S. KinyandaE. The 5-HTTLPR-rs25531 SASA haplotype and chronic stress moderate the association between acute stress and internalizing mental disorders among HIV+ children and adolescents in Uganda.Front. Genet.20211264905510.3389/fgene.2021.649055 33968131
     [Google Scholar]
  79. RadenkovićL. KaranovićJ. Pantović-StefanovićM. Dynamic model of serotonin presynapse and its application to suicide attempt in patients with bipolar disorder.Int. J. Mol. Sci.2025269408510.3390/ijms26094085 40362322
     [Google Scholar]
  80. FeltenA. PliegerT. ReuterM. Predicting anxiety-related personality traits by means of serotonergic VNTR variants STin2 and 5-HTTLPR.J Mood Anxiety Disord2023410003110.1016/j.xjmad.2023.100031
     [Google Scholar]
  81. ZhangP. GaoY. HuY. Altered fractional amplitude of low-frequency fluctuation in anxious Parkinson’s disease.Brain Sci.20231318710.3390/brainsci13010087 36672068
     [Google Scholar]
  82. WilkinsonA.V. SwannA.C. GrahamD.P. Emotional self-regulation, impulsivity, 5-HTTLPR and tobacco use behavior among psychiatric inpatients.J. Affect. Disord.202231163163610.1016/j.jad.2022.05.114 35623482
     [Google Scholar]
  83. GellnerA.K. VoelterJ. SchmidtU. Molecular and neurocircuitry mechanisms of social avoidance.Cell. Mol. Life Sci.20217841163118910.1007/s00018‑020‑03649‑x 32997200
     [Google Scholar]
  84. SteinK. MarufA.A. MüllerD.J. BishopJ.R. BousmanC.A. Serotonin transporter genetic variation and antidepressant response and tolerability: A systematic review and meta-analysis.J. Pers. Med.20211112133410.3390/jpm11121334 34945806
     [Google Scholar]
  85. Kleine SchaarsK. van WestrhenenR. Pharmacogenomics and the management of mood disorders—A review.J. Pers. Med.2023137118310.3390/jpm13071183 37511796
     [Google Scholar]
  86. BradleyP. ShiekhM. MehraV. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.J. Psychiatr. Res.20189610010710.1016/j.jpsychires.2017.09.024 28992526
     [Google Scholar]
  87. LewandrowskiK.U. BlumK. SharafshahA. Genetic and regulatory mechanisms of comorbidity of anxiety, depression and ADHD: A GWAS meta-meta-analysis through the lens of a system biological and pharmacogenomic perspective in 18.5 M subjects.J. Pers. Med.202515310310.3390/jpm15030103 40137419
     [Google Scholar]
  88. BandelowB. MichaelisS. WedekindD. Treatment of anxiety disorders.Dialogues Clin. Neurosci.20171929310710.31887/DCNS.2017.19.2/bbandelow 28867934
     [Google Scholar]
  89. MrozekW. SochaJ. SidorowiczK. Pathogenesis and treatment of depression: Role of diet in prevention and therapy.Nutrition202311511214310.1016/j.nut.2023.112143 37562078
     [Google Scholar]
  90. MasdrakisV.G. BaldwinD.S. Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: A structured review.Ther. Adv. Psychopharmacol.2021112045125321100232010.1177/20451253211002320 33815761
     [Google Scholar]
  91. StrawnJR MillsJA SureshV PerisTS WalkupJT CroarkinPE Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety.J Affect Disord2022298Pt A29230010.1016/j.jad.2021.10.04734728290
     [Google Scholar]
  92. MangoliniV.I. AndradeL.H. Lotufo-NetoF. WangY.P. Treatment of anxiety disorders in clinical practice: A critical overview of recent systematic evidence.Clinics201974131610.6061/clinics/2019/e1316 31721908
     [Google Scholar]
  93. PourkazemT. GhazanfariA. AhmadiR. Comparison of the effectiveness of mindfulness-based stress reduction and compassion-focused therapy on the cognitive emotion regulation in patients with irritable bowel syndrome.Middle East J. Dig. Dis.202315427728410.34172/mejdd.2023.358 38523884
     [Google Scholar]
  94. MaL. WangY. PanL. CuiZ. SchluterP.J. Mindfulness-informed (ACT) and Mindfulness-based Programs (MBSR/MBCT) applied for college students to reduce symptoms of depression and anxiety.J. Behav. Cogn. Ther.202232427128910.1016/j.jbct.2022.05.002
     [Google Scholar]
  95. BhattacharyaS. HofmannS.G. Mindfulness-based interventions for anxiety and depression.Clinics in Integrated Care20231610013810.1016/j.intcar.2023.100138
     [Google Scholar]
  96. KhannaM.S. CarperM. Digital mental health interventions for child and adolescent anxiety.Cognit. Behav. Pract.2022291606810.1016/j.cbpra.2021.05.003
     [Google Scholar]
  97. JohannsenM. NissenE.R. LundorffM. O’TooleM.S. Mediators of acceptance and mindfulness-based therapies for anxiety and depression: A systematic review and meta-analysis.Clin. Psychol. Rev.20229410215610.1016/j.cpr.2022.102156 35483275
     [Google Scholar]
  98. LeeS.H. ChoS.J. Cognitive behavioral therapy and mindfulness-based cognitive therapy for depressive disorders.Adv. Exp. Med. Biol.2021130529531010.1007/978‑981‑33‑6044‑0_16 33834406
     [Google Scholar]
  99. PeggS. HillK. ArgirosA. OlatunjiB.O. KujawaA. Cognitive Behavioral therapy for anxiety disorders in youth: Efficacy, moderators, and new advances in predicting outcomes.Curr. Psychiatry Rep.2022241285385910.1007/s11920‑022‑01384‑7 36370264
     [Google Scholar]
  100. SabriS. RashidN. MaoZ.X. Physical activity and exercise as a tool to cure anxiety and posttraumatic stress disorder.Ment. Illn.20232023112010.1155/2023/4294753
     [Google Scholar]
  101. JermainaN. KusmaediN. MamunA. GaffarV. PurnomoE. MarheniE. Effects of relaxation exercises to reduce anxiety in beginner athletes.Int J Hum Mov Sports Sci20221061275128310.13189/saj.2022.100618
     [Google Scholar]
  102. RidoutSJ RidoutKK LinTY CampbellCI Clinical use of mental health digital therapeutics in a large health care delivery system: Retrospective patient cohort study and provider survey.JMIR Ment Health202411v11i8e5657410.2196/5657439356493
     [Google Scholar]
  103. RajendranA. KellaA. NarayanasamyD. The revolution of digital therapeutics (DTx) in the pharmaceutical industry and their quality impacts.Cureus20241686679210.7759/cureus.66792 39268306
     [Google Scholar]
  104. KwonH. ChoiI.Y. KimD.J. YooJ.H. A review of current digital mental health care applications for anxiety symptoms and future prospects.Psychiatry Investig.202421655156010.30773/pi.2023.0339 38960432
     [Google Scholar]
  105. ArifinM. SekarwanaN. MediawatiA.S. SusilaningsihF.S. Assessing the effectiveness of an e-coaching intervention in improving family support for individuals with mental disorders: A Quasi-experimental approach.J. Multidiscip. Healthc.2023162405241510.2147/JMDH.S417685 37609053
     [Google Scholar]
  106. MaherA.R. ApaydinE.A. RaaenL. MotalaA. BaxiS. HempelS. The use of technology in the clinical care of anxiety: An evidence map.Psychiatr. Serv.202172219519910.1176/appi.ps.202000178 33291972
     [Google Scholar]
  107. LiuZ. RenL. XiaoC. ZhangK. DemianP. Virtual reality aided therapy towards health 4.0: A two-decade bibliometric analysis.Int. J. Environ. Res. Public Health2022193152510.3390/ijerph19031525 35162546
     [Google Scholar]
  108. BlackburnA.M. GoetterE.M. Treatment of anxiety disorders in the digital age.In: Clinical handbook of anxiety disorders: From theory to practice.ChamHumana202029731310.1007/978‑3‑030‑30687‑8_16
     [Google Scholar]
  109. ChoiH. KimB. KimI. Analysis of the status and future direction for digital therapeutics in children and adolescent psychiatry.J. Korean Acad. Child Adolesc. Psychiatry202334419220310.5765/jkacap.230044 37841489
     [Google Scholar]
  110. VindigniG. Exploring digital therapeutics: Game-based and ehealth interventions in mental health care: Potential, challenges, and policy implications.J Biomed Eng Med Imaging202310310.14738/bjhmr.103.14804
     [Google Scholar]
  111. RefoloP. SacchiniD. RaimondiC. SpagnoloA.G. Ethics of digital therapeutics (DTx).Eur. Rev. Med. Pharmacol. Sci.202226186418642310.26355/eurrev_202209_29741 36196692
     [Google Scholar]
  112. HongJ.S. WasdenC. HanD.H. Introduction of digital therapeutics.Comput. Methods Programs Biomed.202120910631910.1016/j.cmpb.2021.106319 34364181
     [Google Scholar]
  113. BuragohainD. KhicharS. DengC. MengY. ChaudharyS. Analyzing metaverse-based digital therapies, their effectiveness, and potential risks in mental healthcare.Sci. Rep.20251511706610.1038/s41598‑025‑00916‑4 40379748
     [Google Scholar]
  114. SayedN. AllawadhiP. KhuranaA. Gene therapy: Comprehensive overview and therapeutic applications.Life Sci.202229412037510.1016/j.lfs.2022.120375 35123997
     [Google Scholar]
  115. ZhouA. RyanJ. Biological embedding of early-life adversity and a scoping review of the evidence for intergenerational epigenetic transmission of stress and trauma in humans.Genes2023148163910.3390/genes14081639 37628690
     [Google Scholar]
  116. RohnT.T. RadinD. BrandmeyerT. Genetic modulation of the HTR2A gene reduces anxiety-related behavior in mice.PNAS Nexus202326pgad17010.1093/pnasnexus/pgad170 37346271
     [Google Scholar]
  117. KvernoK.S. ManganoE. Treatment-resistant depression: Approaches to treatment.J. Psychosoc. Nurs. Ment. Health Serv.202159971110.3928/02793695‑20210816‑01 34459676
     [Google Scholar]
  118. VazA. SalgadoA. PatrícioP. PintoL. Patient-derived induced pluripotent stem cells: Tools to advance the understanding and drug discovery in Major Depressive Disorder.Psychiatry Res.202433911603310.1016/j.psychres.2024.116033 38968917
     [Google Scholar]
  119. JarrinS. FinnD.P. Optogenetics and its application in pain and anxiety research.Neurosci. Biobehav. Rev.201910520021110.1016/j.neubiorev.2019.08.007 31421140
     [Google Scholar]
  120. MottiR. de FalcoB. Traditional herbal remedies used for managing anxiety and insomnia in Italy: An ethnopharmacological overview.Horticulturae202171252310.3390/horticulturae7120523
     [Google Scholar]
  121. Alonso-CastroA.J. Ruiz-PadillaA.J. Ortiz-CortesM. Self-treatment and adverse reactions with herbal products for treating symptoms associated with anxiety and depression in adults from the central-western region of Mexico during the Covid-19 pandemic.J. Ethnopharmacol.202127211395210.1016/j.jep.2021.113952 33610705
     [Google Scholar]
  122. Choque OlssonN. JuthP. Högberg RagnarssonE. LundgrenT. Jansson-FröjmarkM. ParlingT. Treatment satisfaction with cognitive-behavioral therapy among children and adolescents with anxiety and depression: A systematic review and meta-synthesis.J. Behav. Cogn. Ther.202131214719110.1016/j.jbct.2020.10.006
     [Google Scholar]
  123. RenL. FanY. WuW. Anxiety disorders: Treatments, models, and circuitry mechanisms.Eur. J. Pharmacol.202498317699410.1016/j.ejphar.2024.176994 39271040
     [Google Scholar]
  124. PontoneG.M. MillsK.A. Optimal treatment of depression and anxiety in Parkinson’s disease.Am. J. Geriatr. Psychiatry202129653054010.1016/j.jagp.2021.02.037 33648830
     [Google Scholar]
  125. GeronimoA.C.R. MeloE.S.P. SilvaK.R.N. Human health risk assessment of heavy metals and metalloids in herbal medicines used to treat anxiety: Monitoring of safety.Front. Pharmacol.20211277292810.3389/fphar.2021.772928 34858191
     [Google Scholar]
  126. BanuZ. SriC.R. InayetA. BegumF.U. Systemic review of medicinal plants used for the treatment of anxiety.Eur. J. Pharm. Med. Res.2024112139158
     [Google Scholar]
  127. ZhangW. YanY. WuY. Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis.Pharmacol. Res.202217910620410.1016/j.phrs.2022.106204 35378276
     [Google Scholar]
  128. PetrovićB. VukomanovićP. PopovićV. Herbal remedies in the treatment of anxiety disorders.In: AnIntroductiontoMedicinalHerbs.New YorkNova Science Publishers2021205236
     [Google Scholar]
  129. MusaH.H. MusaT.H. OderindeO. Traditional herbal medicine: Overview of research indexed in the scopus database.Advances in Traditional Medicine20232341173118310.1007/s13596‑022‑00670‑2
     [Google Scholar]
  130. TrkuljaV. BarićH. Current research on complementary and alternative medicine (CAM) in the treatment of anxiety disorders: An evidence-based review.Adv. Exp. Med. Biol.2020119141544910.1007/978‑981‑32‑9705‑0_22 32002940
     [Google Scholar]
  131. NimmonsD. AkerN. BurnandA. Clinical effectiveness of pharmacological and non-pharmacological treatments for the management of anxiety in community dwelling people living with dementia: A systematic review and meta-analysis.Neurosci. Biobehav. Rev.202415710550710.1016/j.neubiorev.2023.105507 38097097
     [Google Scholar]
  132. OraczJ. KowalskiS. ŻyżelewiczD. The influence of microwave-assisted extraction on the phenolic compound profile and biological activities of extracts from selected Scutellaria species.Molecules2023289387710.3390/molecules28093877 37175287
     [Google Scholar]
  133. ZanardiR. CarminatiM. FazioV. MaccarioM. VerriG. ColomboC. Add-On treatment with Passiflora incarnata L., herba, during benzodiazepine tapering in patients with depression and Anxiety: A real-world study.Pharmaceuticals202316342610.3390/ph16030426 36986524
     [Google Scholar]
  134. XuT. CockI.E. A review of the sedative, anti-anxiety and immunosti-mulant properties of Withania somnifera (L.) Dunal (Ashwagandha).Pharmacogn. Commun.2023131152310.5530/pc.2023.1.4
     [Google Scholar]
  135. BorrásS. Martínez-SolísI. RíosJ.L. Medicinal plants for insomnia related to anxiety: An updated review.Planta Med.20218710/1173875310.1055/a‑1510‑9826 34116572
     [Google Scholar]
  136. BandopadhyayS. MandalS. GhoraiM. Therapeutic properties and pharmacological activities of asiaticoside and madecassoside: A review.J. Cell. Mol. Med.202327559360810.1111/jcmm.17635 36756687
     [Google Scholar]
  137. MeesakulP. SheaT. WongS.X. KurokiY. CaoS. Hawaiian plants with beneficial effects on sleep, anxiety, and mood, etc.Pharmaceuticals2023169122810.3390/ph16091228 37765036
     [Google Scholar]
  138. KuruvalliG. WankhadeI. WankhedeS. A comprehensive review on the ethno-medicinal and pharmacological properties of Bacopa monnieri.Pharmacogn. Rev.2023173441842510.5530/phrev.2023.17.17
     [Google Scholar]
  139. PanigrahiA.K. SatapathyS. MishraS.K. JenaS.K. Effect of Ocimum sanctum leaf extract in animal models of anxiety.Natl. J. Physiol. Pharm. Pharmacol.20221271084108810.5455/njppp.2022.12.062671202209062022
     [Google Scholar]
  140. MotaharehB. ShahinH. MasoudM. TabandehS. The effects of Melissa officinalis leaf extract on anxiety among patients undergoing orthopedic surgeries.J. Herb. Med.20223110053210.1016/j.hermed.2021.100532
     [Google Scholar]
  141. YooO. ParkS.A. Anxiety-reducing effects of lavender essential oil inhalation: A systematic review.Healthc20231122297810.3390/healthcare11222978 37998470
     [Google Scholar]
  142. SavageK. SarrisJ. HughesM. Neuroimaging insights: Kava’s (Piper methysticum) effect on dorsal anterior cingulate Cortex GABA in generalized anxiety disorder.Nutrients20231521458610.3390/nu15214586 37960239
     [Google Scholar]
  143. KamatD. Al-AjlouniY.A. HallR.C.W. The therapeutic impact of Plant-Based and Nutritional supplements on anxiety, depressive symptoms and sleep quality among adults and Elderly: A systematic review of the literature.Int. J. Environ. Res. Public Health2023206517110.3390/ijerph20065171 36982079
     [Google Scholar]
  144. SiddiquiN. TalibM. TripathiP.N. KumarA. SharmaA. An insight into the neurodegenerative exploration of Baicalein: A review.Health Sci. Rev202410017210.1016/j.hsr.2024.100172
     [Google Scholar]
  145. KupcovaI. DanisovicL. GrgacI. HarsanyiS. Anxiety and depression: What do we know of neuropeptides?Behav. Sci.202212826210.3390/bs12080262 36004833
     [Google Scholar]
  146. MukhinaA.Y. MishinaE.S. BobyntsevI.I. Morphological changes in the large intestine of rats subjected to chronic restraint stress and treated with selank.Bull. Exp. Biol. Med.2020169228128510.1007/s10517‑020‑04868‑9 32651826
     [Google Scholar]
  147. MizushigeT. Neuromodulatory peptides: Orally active anxiolytic-like and antidepressant-like peptides derived from dietary plant proteins.Peptides202114217056910.1016/j.peptides.2021.170569 33984426
     [Google Scholar]
  148. FonsecaI.C.F. Castelo-BrancoM. CavadasC. AbrunhosaA.J. PET imaging of the neuropeptide Y system: A systematic review.Molecules20222712372610.3390/molecules27123726 35744852
     [Google Scholar]
  149. TanakaM. YamadaS. WatanabeY. The role of neuropeptide Y in the nucleus accumbens.Int. J. Mol. Sci.20212214728710.3390/ijms22147287 34298907
     [Google Scholar]
  150. ShendeP. DesaiD. Physiological and therapeutic roles of neuropeptide Y on biological functions.Adv. Exp. Med. Biol.20201237374710.1007/5584_2019_427 31468359
     [Google Scholar]
  151. ClarkC.M. ClarkR.M. HoyleJ.A. DicksonT.C. Pathogenic or protective? Neuropeptide Y in amyotrophic lateral sclerosis.J. Neurochem.2021156327328910.1111/jnc.15125 32654149
     [Google Scholar]
  152. SalluzzoM. CarboniL. Anxiety-Like Behaviors and Neuropeptide Y, Tachykinins and Beyond.In: Handbook of the Biology and Pathology of Mental Disorders.ChamSpringer202412110.1007/978‑3‑031‑32035‑4_122‑1
     [Google Scholar]
  153. Al JowfG.I. AhmedZ.T. ReijndersR.A. de NijsL. EijssenL.M.T. To predict, prevent, and manage post-traumatic stress disorder (PTSD): A review of pathophysiology, treatment, and biomarkers.Int. J. Mol. Sci.2023246523810.3390/ijms24065238 36982313
     [Google Scholar]
  154. YamadaS. IslamM.S. van KootenN. Neuropeptide Y neurons in the nucleus accumbens modulate anxiety-like behavior.Exp. Neurol.202032711321610.1016/j.expneurol.2020.113216 32014439
     [Google Scholar]
  155. BotticelliL. Micioni Di BonaventuraE. UbaldiM. CiccocioppoR. CifaniC. Micioni Di BonaventuraM. The Neural Network of Neuropeptide S (NPS): Implications in food intake and gastrointestinal functions.Pharmaceuticals202114429310.3390/ph14040293 33810221
     [Google Scholar]
  156. KushikataT. HirotaK. SaitoJ. TakekawaD. Roles of neuropeptide S in anesthesia, analgesia, and sleep.Pharmaceuticals202114548310.3390/ph14050483 34069327
     [Google Scholar]
  157. TobinskiA.M. RappeneauV. Role of the neuropeptide S system in emotionality, stress responsiveness and addiction-like behaviours in rodents: Relevance to stress-related disorders.Pharmaceuticals202114878010.3390/ph14080780 34451877
     [Google Scholar]
  158. Markiewicz-GospodarekA. KusztaP. BajJ. DobrowolskaB. MarkiewiczR. Can neuropeptide S be an indicator for assessing anxiety in psychiatric disorders?Front. Public Health20221087243010.3389/fpubh.2022.872430 35558538
     [Google Scholar]
  159. LiS. GuoC. ZhangX. Self-assembling modified neuropeptide S enhances nose-to-brain penetration and exerts a prolonged anxiolytic-like effect.Biomater. Sci.20219134765477710.1039/D1BM00380A 34037635
     [Google Scholar]
  160. BhargavaA. Unraveling corticotropin-releasing factor family-orchestrated signaling and function in both sexes.Vitam. Horm.2023123276510.1016/bs.vh.2023.01.009 37717988
     [Google Scholar]
  161. MbiydzenyuyN.E. QuluL.A. Stress, hypothalamic-pituitary-adrenal axis, hypothalamic-pituitary-gonadal axis, and aggression.Metab. Brain Dis.20243981613163610.1007/s11011‑024‑01393‑w 39083184
     [Google Scholar]
  162. GotoS. KojimaN. KomoriM. Vitamin C deficiency alters the transcriptome of the rat brain in a glucocorticoid-dependent manner, leading to microglial activation and reduced neurogenesis.J. Nutr. Biochem.202412810960810.1016/j.jnutbio.2024.109608 38458474
     [Google Scholar]
  163. YangX. GengF. Corticotropin‐releasing factor signaling and its potential role in the prefrontal cortex‐dependent regulation of anxiety.J. Neurosci. Res.2023101121781179410.1002/jnr.25238 37592912
     [Google Scholar]
  164. CsabafiK. IbosK.E. BodnárÉ. FilkorK. SzakácsJ. BagosiZ. A brain region-dependent alteration in the expression of vasopressin, corticotropin-releasing factor, and their receptors might be in the background of Kisspeptin-13-induced hypothalamic-pituitary-adrenal axis activation and anxiety in rats.Biomedicines2023119244610.3390/biomedicines11092446 37760887
     [Google Scholar]
  165. BertagnaN.B. dos SantosP.G.C. QueirozR.M. FernandesG.J.D. CruzF.C. MiguelT.T. Involvement of the ventral, but not dorsal, hippocampus in anxiety-like behaviors in mice exposed to the elevated plus maze: Participation of CRF1 receptor and PKA pathway.Pharmacol. Rep.2021731577210.1007/s43440‑020‑00182‑3 33175366
     [Google Scholar]
  166. AgogliaA.E. TellaJ. HermanM.A. Sex differences in corticotropin releasing factor peptide regulation of inhibitory control and excitability in central amygdala corticotropin releasing factor receptor 1-neurons.Neuropharmacology202018010829610.1016/j.neuropharm.2020.108296 32950560
     [Google Scholar]
  167. LawrenceS. ScofieldR.H. Post traumatic stress disorder associated hypothalamic-pituitary-adrenal axis dysregulation and physical illness.Brain Behav. Immun. Health20244110084910.1016/j.bbih.2024.100849 39280087
     [Google Scholar]
  168. CaselloS.M. FloresR.J. YarurH.E. Neuropeptide system regulation of prefrontal cortex circuitry: Implications for neuropsychiatric disorders.Front. Neural Circuits20221679644310.3389/fncir.2022.796443 35800635
     [Google Scholar]
  169. MishraS. GrewalJ. WalP. BhivshetG.U. TripathiA.K. WaliaV. Therapeutic potential of vasopressin in the treatment of neurological disorders.Peptides202417417116610.1016/j.peptides.2024.171166 38309582
     [Google Scholar]
  170. GomesD.A. de Almeida BeltrãoR.L. de OliveiraJuniorFM Vasopressin and copeptin release during sepsis and septic shock.Peptides202113617043710.1016/j.peptides.2020.170437 33181268
     [Google Scholar]
  171. GlavašM. Gitlin-DomagalskaA. DębowskiD. PtaszyńskaN. ŁęgowskaA. RolkaK. Vasopressin and its analogues: From natural hormones to multitasking peptides.Int. J. Mol. Sci.2022236306810.3390/ijms23063068 35328489
     [Google Scholar]
  172. LagoT.R. BrownsteinM.J. PageE. The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: A randomized proof-of-concept study.Psychopharmacology202123892393240310.1007/s00213‑021‑05861‑4 33970290
     [Google Scholar]
  173. TakayanagiY. OnakaT. Roles of oxytocin in stress responses, allostasis and resilience.Int. J. Mol. Sci.202123115010.3390/ijms23010150 35008574
     [Google Scholar]
  174. YoonS. KimY.K. Possible oxytocin-related biomarkers in anxiety and mood disorders.Prog. Neuropsychopharmacol. Biol. Psychiatry202211611053110.1016/j.pnpbp.2022.110531 35150782
     [Google Scholar]
  175. GrinevichV. NeumannI.D. Brain oxytocin: How puzzle stones from animal studies translate into psychiatry.Mol. Psychiatry202126126527910.1038/s41380‑020‑0802‑9 32514104
     [Google Scholar]
  176. YinH. JiangM. HanT. XuX. Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications.Peptides202417617121110.1016/j.peptides.2024.171211 38579916
     [Google Scholar]
  177. XuY. GuanX. ZhouR. GongR. Melanocortin 5 receptor signaling pathway in health and disease.Cell. Mol. Life Sci.202077193831384010.1007/s00018‑020‑03511‑0 32248247
     [Google Scholar]
  178. DinparastisalehR. MirsaeidiM. Antifibrotic and anti-inflammatory actions of α-melanocytic hormone: New roles for an old player.Pharmaceuticals20211414510.3390/ph14010045 33430064
     [Google Scholar]
  179. HouZ.S. WenH.S. Neuropeptide Y and melanocortin receptors in fish: Regulators of energy homeostasis.Mar. Life Sci. Technol.202241425110.1007/s42995‑021‑00106‑x 37073356
     [Google Scholar]
  180. MunY. KimW. ShinD. Melanocortin 1 receptor (MC1R): Pharmacological and therapeutic aspects.Int. J. Mol. Sci.202324151215210.3390/ijms241512152 37569558
     [Google Scholar]
  181. Micioni Di BonaventuraE. BotticelliL. Del BelloF. Investigating the role of the central melanocortin system in stress and stress-related disorders.Pharmacol. Res.202218510652110.1016/j.phrs.2022.106521 36272641
     [Google Scholar]
  182. MarkovD.D. DolotovO.V. GrivennikovI.A. The melanocortin system: A promising target for the development of new antidepressant drugs.Int. J. Mol. Sci.2023247666410.3390/ijms24076664 37047638
     [Google Scholar]
/content/journals/cnr/10.2174/0115672026394052250808075022
Loading
Future Directions in Anxiolytic Therapy: A Comprehensive Review of Novel Targets and Strategies
Curr Neurovasc Res 22, 115 (2025); https://doi.org/10.2174/0115672026394052250808075022
/content/journals/cnr/10.2174/0115672026394052250808075022
/content/journals/cnr/10.2174/0115672026394052250808075022
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Anxiety disorders; anxiety treatment advancements; combination therapy; digital therapeutics; gene therapy; herbal therapy; microbiome modulation; novel therapeutic targets; peptide-based therapy; personalized medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test